Study Finds Pharmacotyping Pediatric Leukemia Offers Blueprint to Better Precision Medicine
Researchers at St. Jude’s Children Research Hospital have conducted a new study looking into drug sensitivity among patients with acute lymphoblastic leukemia across a variety of genetic subtypes. Acute lymphoblastic leukemia is a common childhood cancer that affects white blood cells. It is estimated that roughly 98% of children suffering from this cancer type will experience remission after a few weeks of treatment. Of this number, almost 90% will be cured. Current treatments for acute lymphoblastic leukemia are risk adapted, which means that chemotherapy is based on leukemia genomics, clinical features and the extent of minimal residual disease. The researchers’…
